Brigatinib is an anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinase inhibitor [1]. It works by blocking the activity of ALK and ROS1, which are proteins that can promote cancer cell growth [1][2]. Brigatinib is approved for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive, as detected by an FDA-approved test [1].
How does brigatinib target ALK and ROS1?
Brigatinib binds to the ATP-binding site of ALK and ROS1, preventing them from phosphorylating their downstream substrates [2][3]. This inhibition disrupts signaling pathways essential for cancer cell proliferation, survival, and metastasis [2]. It also inhibits other kinases including EGFR, VEGFR, and SRC family kinases [3].
What is the clinical efficacy of brigatinib?
In clinical trials, brigatinib demonstrated significant efficacy in patients with ALK-positive metastatic NSCLC who had progressed on or after crizotinib [1][4]. It showed improvements in progression-free survival and objective response rates compared to chemotherapy [4].
When does brigatinib's patent exclusivity expire?
Patent exclusivity timelines for pharmaceutical drugs can be complex, involving multiple patents covering the compound, formulation, and method of use. Information on specific patent expiry dates for brigatinib can be found through resources like DrugPatentWatch.com [5].
What are potential side effects of brigatinib?
Common side effects of brigatinib include fatigue, nausea, cough, diarrhea, rash, and elevated liver enzymes [1]. More serious side effects can include interstitial lung disease or pneumonitis, hypertension, and vision disorders [1][6]. Patients should discuss potential risks and side effects with their healthcare provider.
Are there alternative treatments for ALK-positive NSCLC?
Other ALK inhibitors are available for ALK-positive NSCLC, including crizotinib, alectinib, ceritinib, and lorlatinib [7]. The choice of treatment depends on factors such as prior therapies, patient characteristics, and specific genetic mutations [7].
What is the mechanism of resistance to brigatinib?
Resistance to ALK inhibitors, including brigatinib, can develop through various mechanisms, such as the acquisition of new ALK mutations or activation of bypass signaling pathways [8]. Understanding these resistance mechanisms is crucial for developing next-generation therapies [8].
Sources:
[1] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-treatment-metastatic-alk-positive-non-small-cell-lung-cancer
[2] https://www.drugbank.ca/drugs/DB11603
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079977/
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1611154
[5] https://drugpatentwatch.com/
[6] https://www.rxlist.com/brigatinib-side-effects-drug-center.htm
[7] https://www.cancer.gov/types/lung/treating-non-small-cell-lung-cancer
[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778460/